Industry wants more clarity on NGS for assessing gene therapy safety

17 Jul 2026 This Week at FDA: FDA staff raise concerns about peptide conflicts, top Democrat wants DOGE investigation, and more Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, FDA staff raised concerns internally about conflicts of interest ahead of a panel on peptides next week, a top Democrat is seeking an investigation into the effects of the DOGE cuts on FDA, and the agency’s acting commissioner backtracked on some policies issued by his predecessor. This Week at FDA